Compare
Sunshine Biopharma Inc. vs Lftd Partners Inc. vs Verrica Pharmaceuticals Inc. vs BGM Group Ltd.
| Latest fiscal year | Sunshine Biopharma Inc. SBFM | Lftd Partners Inc. LIFD | Verrica Pharmaceuticals Inc. VRCA | BGM Group Ltd. BGM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-09-30 |
| Revenue | $36.31M | $36.92M | $35.58M | $37.92M |
| Revenue growth (YoY) | +4.1% | -1.1% | +370.2% | +51.1% |
| Gross margin | 33.8% | 34.2% | n/a | 16.6% |
| Operating margin | -17.2% | 2.5% | -34.2% | -33.2% |
| Net margin | -16.5% | -67.3% | -50.3% | -52.6% |
| Net income | -$5.98M | -$24.86M | -$17.89M | -$19.94M |
| EPS (Diluted) | n/a | -$1.68 | -$1.68 | -$0.18 |
| Operating cash flow | -$5.33M | $1.32M | -$17.63M | -$2.37M |
| Free cash flow | -$5.51M | $1.20M | -$17.63M | -$3.94M |
| Cash & equivalents | n/a | $1.77M | $30.15M | $9.82M |
| Total assets | $30.08M | $19.27M | $47.13M | $433.81M |
| Total liabilities | $7.04M | $6.64M | $22.39M | $41.92M |
| Shareholders' equity | $23.04M | $12.63M | $24.74M | $391.90M |
| Return on year-end equity | -25.9% | -196.8% | -72.3% | -5.1% |
| Shares outstanding | 4.91M | 14.82M | 17.18M | 200.62M |
Revenue, most recent five fiscal years
| Fiscal year | Sunshine Biopharma Inc. | Lftd Partners Inc. | Verrica Pharmaceuticals Inc. | BGM Group Ltd. |
|---|---|---|---|---|
| Latest | $36.31M Ended 2025-12-31 | $36.92M Ended 2025-12-31 | $35.58M Ended 2025-12-31 | $37.92M Ended 2025-09-30 |
| 1 year earlier | $34.87M Ended 2024-12-31 | $37.33M Ended 2024-12-31 | $7.57M Ended 2024-12-31 | $25.10M Ended 2024-09-30 |
| 2 years earlier | $24.09M Ended 2023-12-31 | $51.61M Ended 2023-12-31 | $5.12M Ended 2023-12-31 | $46.47M Ended 2023-09-30 |
| 3 years earlier | $4.35M Ended 2022-12-31 | $57.42M Ended 2022-12-31 | $9.03M Ended 2022-12-31 | $64.86M Ended 2022-09-30 |
| 4 years earlier | $228.4K Ended 2021-12-31 | $31.66M Ended 2021-12-31 | $12.00M Ended 2021-12-31 | $57.10M Ended 2021-09-30 |